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Case Report
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Introduction
Secondary renal involvement in advanced non-
Hodgkin’s lymphomas is quite common, but primary
renal lymphoma (PRL) is a rare disease. It accounts
for 0.7% of all extra-nodal lymphomas in North
America and 0.1% in Japan, and 65 cases have been
reported in the worldwide literature. PRL is also a
debated disease because kidneys do not contain
lymphatic tissue [1,2]. General agreement exists about
the criteria needed to deﬁne the diagnosis of PRL: (i)
renal failure as the ﬁrst presentation in the absence of
other causes of renal impairment; (ii) rapid improve-
ment of renal function following therapy; (iii) increase
of the kidneys’ size without any urinary tract obstruc-
tion; (iv) absence of other nodal or extra-nodal
involvement; and (v) deﬁnite diagnosis made by histo-
logical examination.
The median age at PRL diagnosis is 64 years, and the
disease is more frequent in males than in females. Acute
renal failure, ﬂank pain and detection of a renalmass are
the most frequent manifestations [3]. Renal failure may
result from a large variety of causes, such as lympho-
matous inﬁltration of renal tissue or hypercalcaemia [4].
Histological examination is mandatory, as clinical and
radiological ﬁndings often evoke renal carcinoma [5].
The prognosis is poor, but long-term survivors have
been reported occasionally after surgical resection and
combination chemotherapy, in unilateral renal lym-
phoma [2]. Bilateral renal involvement has a prevalence
of 43% [6]: in this case, the prognosis is very severe and
chemotherapy is the usual proposed treatment because
surgery has never been described (Table 1).
We report a case of bilateral PRL successfully
treated by surgical resection leading to a three-quarters
ablation of native renal mass followed by combination
chemotherapy.
Case
A 46-year-old male with a history of chronic renal
failure (creatinine 230 mmol/l; creatinine clearance
45ml/min) from chronic pyelonephritis was admitted
in October 1997 due to rapid worsening of renal failure
and hypercalcaemia. Ten months earlier, following
sonographic detection of a mass in the right kidney,
the patient had been studied in another hospital where
the histological diagnosis of inﬂammatory pseudo-
tumour of the right kidney was made by computed
tomography (CT)-guided renal biopsy. Cortical scar-
ring and caliceal deformity of the left kidney was also
described and diagnosed as chronic pyelonephritis. At
admission, physical examination was unremarkable;
no oedema, dyspnoea, fever, pruritus or body weight
loss were present. Arterial blood pressure was 140–
80mmHg, body weight 97 kg, body mass index 30.2
kg/m2. Biochemistry showed serum creatinine 521
mmol/l, creatinine clearance 15ml/min, serum calcium
3.45mmol/l, intact parathyroid hormone 6 pg/ml, 25-
hydroxy vitamin D 44 pg/ml, 1,25 dihydroxy vitamin
D 96 pg/ml, lactate dehydrogenase 620U/l. The white
blood cell count was 8.7 109/l (N 56, L 30, M 10, B
0.5, E 1.6%). The red blood cell count was 5.1 1012/l,
haemoglobin 2.17mmol/l and haematocrit 0.44. Urine
analysis showed microhaematuria (40–50 red cells) and
mild proteinuria (50mg/dl).
Values found to be in the normal range were those
for serum uric acid, phosphorus, sodium, potassium,
glucose, cholesterol, triglycerides, bilirubin, aspartate
aminotransferase, alanine aminotransferase, alkaline
phosphatase, serum and urine protein electophoresis,
hepatitis C virus and hepatitis B virus.
The patient’s chest X-rays were normal. Abdominal
sonography showed an enlarged right kidney diameter
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with irregular borders, mesorenal scarring and hyper-
trophic areas; the left kidney measured 9 cm in
diameter with irregular borders. No signs of stones or
urinary tract obstruction were detected. No enlarged
lymph node was detected by sonography of the neck,
inguinal and axillary regions.
Hypercalcaemia was treated by saline and furose-
mide, leading to normalization of serum calcium to
2.5–2.7mmol/l and progressive reduction of serum
creatinine to 309 mmol/l.
Abdominal magnetic resonance conﬁrmed a right
kidney of increased size, with multiple nodules and
complete subverting of the normal structure. The
larger nodule measuring 8 cm diameter was located in
the upper posterior region of the right kidney; a nodule
involving the upper pole of the left kidney was also
detected, whereas the remaining kidney tissue appeared
preserved (Figure 1). No abnormalities were described
as far as lymph nodes, liver or spleen were concerned.
Fine-needle percutaneous renal biopsy was per-
formed using a free-hand ultrasound-guided procedure
on the lower pole of the right kidney where nodular
hypertrophic areas were detected. Microscopy showed
the presence of some atypical lymphocytes.
Suspicion of a cancer or of a lymphoproliferative
disease with bilateral renal involvement arose. There-
fore, the patient underwent xipho-pubical laparotomy.
The right kidney appeared completely subverted by
proliferative tissue, while exploration of the left kidney
conﬁrmed a proliferative lesion apparently limited to
its upper region.
Consequently, right radical nephrectomy and upper
pole resection of the left kidney were performed,
preserving approximately half of the left kidney. Seven
inter-aortic lymph nodes were sampled. The abdom-
inal exploration was unremarkable. The right kidney
measured 15 8 8 cm and the removed portion of
the left kidney measured 6 3 3 cm.
Histological examination showed a diffuse, large
B-cell lymphoma (REAL classiﬁcation), centroblastic
variant, which diffusely inﬁltrated interstitium and
glomeruli. This variant was composed of medium to
large sized lymphoid cells with oval to round, vesicular
nuclei with ﬁne chromatin and 2–3 membrane-bound
nucleoli. This case was characterized by many multi-
lobated cells. The immuno-phenotype was CD20þ,
CD79aþ and Bcl-2–/þ. These ﬁndings were observed
both in the right and in the left kidney tissue. However,
adrenal glands, peri-renal fat or inter-aortic lymph
nodes were not involved.
During the days following nephrectomy, serum
creatinine improved to 247 mmol/l together with reduc-
tion of serum calcium (2.3mmol/l) and calcitriol
(6.0 pg/ml) serum levels.
Table 1. List of the bilateral PMLs described in the literature, their treatment and outcome
Year Author Age/sex Treatment Follow-up (months) Outcome
1946 Ferifeld 17/M Rx-therapy <12 Death
1950 Allen 41/M Rx-therapy <12 Death
1951 Davis 67/M – <12 Death
1976 Klener 20/M Rx-chemotherapy <12 Death
1980 Coggins 30/M Rx-therapy 6 Remission
1983 Laxer 14/M Rx-therapy 1 Remission
1983 Gilboa 5/M Chemotherapy 15 Death
1986 Camitta 3/F Rx-chemotherapy 36 Remission
1987 Truong 59/M Rx-chemotherapy 13 Death
1987 Truong 26/M Chemotherapy 5 Death
1987 Koolen 61/M Chemotherapy 1.5 Death
1988 Berard 60/M Chemotherapy 2 Remission
1988 Leoncini 50/F Chemotherapy 6 Remission
1989 Kutluk 4/M Chemotherapy >14 Remission
1989 Paganelli 53/F Chemotherapy 1 Death
1990 Mijake 47/M Chemotherapy 17 Remission
1991 Dobkin 10/M Chemotherapy 29 Remission
1991 Jeandel 70/F Chemotherapy 1 Death
1991 Sheil 29/F Chemotherapy 3 Death
1992 Van Gelder 58/F Chemotherapy 10 Death
1992 Carrasco 64/M Rx-chemotherapy 24 Remission
1992 Mills 77/F Chemotherapy 2 Death
1993 Kindle 49/M Chemotherapy ? Unknown
1993 Vandermolen 58/F Chemotherapy 14 Remission
1994 Malbrain 45/M Chemotherapy 31 Remission
1994 Brouland 57/F Rx-chemotherapy 5 Death
1994 Arraz Arija 49/F Chemotherapy 3 Death
1994 Arraz Arija 5/F Chemotherapy 24 Death
1994 Arraz Arija 4/M Chemotherapy 14 Death
1995 Okuno 63/F Chemotherapy 12 Death
1996 Baldus 72/F Chemotherapy 7 Death
2000 Stallone 22/M Chemotherapy 12 Death
2001 O’Riondan 52/M Chemotherapy 13 Death
2002 Gellrich 62/M Chemotherapy 2 Death




















Fig. 1. Nuclear magnetic resonance before surgery. Two coronal sections showing (a) enlargement and complete structural subverting of the
right kidney; and (b) a mass involving the upper pole of the left kidney, with the remaining kidney tissue apparently preserved.




















Additional post-operative staging, including whole
body CT and bone marrow biopsy, did not show any
abnormality or lymphomatous localization.
Six months after surgery, re-staging of the disease
was carried out, leading to detection of a bone marrow
inﬁltration. Translocation of the Bcl2 gene was detected
using polymerase chain reaction (PCR) for clonal
immunoglobulin heavy chain (IgH) gene rearrange-
ment [7]. Thus the patient underwent chemotherapy
according to the Pro-MECE-CytaBOM schedule and,
after four cycles, residual inﬁltration of the bone
marrow was detected by PCR analysis for IgH
rearrangement. Therefore, a second line chemotherapy
was performed according to the Flu-Ctx-Idec protocol
(four cycles) [8]. Successive examination did not show
any relapse and renal function remained stable with
time; serum creatinine ranged between 186 and 210
mmol/l. Follow-up consisted of regular physical exam-
ination and biochemistry. Bone marrow biopsy, chest
X-ray and sonography were performed every 6 months
for 3 years, and then once a year. Abdomen CT scans
were performed every year for the ﬁrst 3 years and then
every 2 years. At this time, 67 months after surgery and
36 months after the end of the chemotherapy, no sign
of disease relapse has been detected. Serum creatinine
remains stable at 186 mmol/l (Figure 2).
Discussion
Although a number of reported PRL cases are in fact
questionable due to incomplete staging or the presence
of extra-renal involvement at the time of diagnosis,
revision of the available literature suggests that
PRL does exist [2]. Our case fulﬁlled the diagnostic
criteria for identiﬁcation of a PRL: acute renal failure
at presentation, enlargement of the kidney, rapid
improvement of renal function after treatment, diag-
nosis made by histology of the renal mass, and absence
of other organ or nodal involvement.
Historically, the patient has been diagnosed with a
chronic pyelonephritis and a pseudo-inﬂammatory
tumour in the right kidney. It is known that this lesion
can precede the onset of a lymphoproliferative disease.
Moreover, as far as the involvement of other extra-
nodal organs is concerned, the lymphoid tissue formed
by chronic inﬂammatory disease is regarded as the
source for the development of malignant lymphoma [9].
The rapid deterioration of the residual renal func-
tion was likely to have been related to parenchyma
inﬁltration and to the hypercalcaemia, probably induced
by vitamin D overproduction from the lymphoid cell
mass. Accordingly, after restoration of normal calcium
levels and subtotal ablation of the renal mass, renal
function did ameliorate and returned to the patient’s
basal values (Figure 2).
Because of the low incidence of this disease, ran-
domized studies aiming to compare different therapy
approaches have not been reported. Systemic chemo-
therapy, with or without radiotherapy, is a widely used
treatment for PRL [10], as well as the option of surgery
in the case of PRL affecting one kidney.
The limited available literature reports that the prog-
nosis of patients affected by PRL is poor, despite no
disseminated disease. Chemotherapy usually improves
or normalizes the renal function, but the few cases
reported showed a high prevalence of deaths because of
rapid relapse or infections incurred in the course of
neutropenia. Long-term survivors occasionally have
been reported after combined surgery–chemotherapy
treatment where one kidney is involved [1]. The patients
whose lymphomatous masses were removed completely
by surgical resection, and who were treated by
Fig. 2. Behaviour of serum creatinine with time, from December 1996 to June 2003. Body weight is also reported.




















combination chemotherapy, had longer disease-free
and overall survival: this usually occurs in monolateral
cases. Patients with bilateral involvement or with
residual lymphoma mass after surgical resection show
a very bad prognosis. Our patient showed bilateral renal
involvement with no signs of other nodal or extra-nodal
localization. Bone marrow involvement was found only
several months following the surgical resection, and
nodal involvement was never detected. This phenom-
enon is difﬁcult to interpret, but certainly this is not in
keeping with a lymphomatous inﬁltration of the kidney
in disseminated lymphoma.
Bilateral renal lymphomas are usually treated by
aggressive chemotherapy as front line therapy [1,5]:
this approach could preserve the organ function, but
generally the prognosis is poor. Alternatively, bilateral
nephrectomy invariably leads to the need for dialysis
treatment.
In our patient, the resection of the apparent tumour
mass preserved approximately one-quarter residual
renal mass which successfully allowed the patient to
avoid dialysis. The choice of initial surgery depended
on the need for a deﬁnite diagnosis, on the presence
of an underlying chronic renal failure and on the
importance of the tumour mass.
The present case report suggests that surgery can be
beneﬁcial in the treatment of renal lymphoma with
bilateral involvement. This kind of treatment was
possible because the left kidney had macroscopic
involvement limited to the upper pole. Although
microscopic involvement could also be present in the
remaining renal tissue, a conservative surgical resec-
tion was possible in the left kidney, allowing for a
residual renal function sufﬁcient to make the patient
free from the need for dialysis. The tumour mass was
dramatically reduced, thus increasing the likelihood of
success of the ensuing chemotherapy treatment. A 67
month period of survival in bilateral renal lymphoma
has been never described in the literature: we believe
that, as is typical with other types of cancers, reduction
of tumour cell mass is a crucial point for successful
treatment and response to chemotherapy.
Table 1 lists the cases of PRL with involvement of
both kidneys which exist in the literature. The overall
poor prognosis is evident, as only 11 cases of remission
at 1–36 months are reported. Various combined
chemotherapy regimens were the main therapeutic
strategy adopted, but surgery was never described.
Actually, the urological intervention represents the
most original aspect of the present case and it is likely
that this could have contributed to the favourable
outcome of the disease by means of a critical reduction
of neoplastic cell mass giving more chance of a better
response to chemotherapy. The surgical approach we
used is the same as is usually performed in bilateral
renal cancer, i.e. the removal of as much tumour mass
as possible, provided there is preservation of enough
(macroscopically) tumour-free kidney tissue.
In conclusion, this case report shows a case of
bilateral PRL successfully treated by extensive surgical
resection and combination chemotherapy. It is difﬁcult
to discuss the relative role of surgery and chemother-
apy in the favourable outcome of this patient. Never-
theless, the unusual long-term remission, together
with preservation of a residual renal function, shows
that surgery, in association with a combined chemo-
therapy protocol, may be an option in selected cases of
bilateral PRL.
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